Dr. Hong Song received his MD from Tulane University School of Medicine and a Ph.D. in Chemical Engineering from Tulane University. He performed research in targeted radionuclide therapy as a postdoctoral fellow at the Johns Hopkins University. Following medical school, he joined Dual pathway Nuclear Medicine and Diagnostic Radiology residency at Stanford. 

His current research interests include PSMA PET in biochemically recurrent prostate cancer and DOTATATE PET in PRRT for neuroendocrine tumors. Much of his group's research focuses on translational molecular imaging and radiopharmaceutical therapy, with an emphasis on developing novel theranostic agents and strategies for cancer diagnosis and therapy.